Monopar Therapeutics Stock Surges on Clinical Progress and Analyst Optimism

Shares of Monopar Therapeutics experienced a significant rally, propelled by encouraging clinical trial developments and a wave of positive analyst coverage. The biotech firm’s stock posted notable gains in the latest trading session.

A series of new analyst initiations has generated considerable market enthusiasm for Monopar. The consensus view is overwhelmingly bullish, with multiple firms issuing positive ratings and substantial price targets.

• Raymond James commenced coverage with a Strong Buy rating and an $80 price objective.
• Oppenheimer initiated coverage with an Outperform recommendation and a $77 target, highlighting the drug’s differentiated mechanism of action.
• Cantor Fitzgerald reaffirmed its Overweight stance with a $74 price target.
• HC Wainwright started coverage with a Buy rating Read more...